Cargando…
Time-Resolved Profiling Reveals ATF3 as a Novel Mediator of Endocrine Resistance in Breast Cancer
SIMPLE SUMMARY: Breast cancer is one of the leading causes of death for women worldwide. Patients whose tumors express estrogen receptor α (ERα) are the vast majority and are mostly treated with targeted endocrine therapy. However, resistance development poses an urgent clinical problem and the mech...
Autores principales: | Borgoni, Simone, Sofyalı, Emre, Soleimani, Maryam, Wilhelm, Heike, Müller-Decker, Karin, Will, Rainer, Noronha, Ashish, Beumers, Lukas, Verschure, Pernette J., Yarden, Yosef, Magnani, Luca, van Kampen, Antoine H.C., Moerland, Perry D., Wiemann, Stefan |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7650760/ https://www.ncbi.nlm.nih.gov/pubmed/33050633 http://dx.doi.org/10.3390/cancers12102918 |
Ejemplares similares
-
Candidate methylation sites associated with endocrine therapy resistance in ER+/HER2- breast cancer
por: Soleimani Dodaran, Maryam, et al.
Publicado: (2020) -
Clonal heterogeneity in ER+ breast cancer reveals the proteasome and PKC as potential therapeutic targets
por: Beumers, Lukas, et al.
Publicado: (2023) -
Epigenetic Editing: targeted rewriting of epigenetic marks to modulate expression of selected target genes
por: de Groote, Marloes L., et al.
Publicado: (2012) -
The dynamics of early-state transcriptional changes and aggregate formation in a Huntington’s disease cell model
por: van Hagen, Martijn, et al.
Publicado: (2017) -
The volumes and transcript counts of single cells reveal concentration homeostasis and capture biological noise
por: Kempe, Hermannus, et al.
Publicado: (2015)